mRNA– tag –
-
Serina Therapeutics Non-Exclusively Licenses POZ Polymer Technology for LNP Drug Delivery Formulations to Pfizer, Accelerating Clinical Development of Investigational Drug SER-252
Serina Therapeutics USA Overview Serina Therapeutics has entered a non-exclusive licensing agreement with Pfizer for its proprietary POZ polymer technology for lipid nanoparticle (LNP) drug delivery formulations. This partnership is part... -
Integrated LNP Composition and Ligand Targeting Dramatically Enhances Pancreatic Beta Cell-Directed RNA Delivery
ACS Nano USA Overview Engineering lipid nanoparticles (LNPs) through integrated compositional and ligand targeting dramatically enhances pancreatic beta cell-directed RNA delivery. Systematically varying the species and molar ratios of t... -
RiboX Therapeutics Receives FDA IND Clearance for RXIM002, the First Circular RNA-Based In Vivo CAR Therapy for Autoimmune Cytopenias
BioSpace USA Overview RiboX Therapeutics has received FDA Investigational New Drug (IND) clearance for RXIM002, a circular RNA (circRNA)-based in vivo CAR therapy targeting autoimmune cytopenias. RXIM002 is the first in vivo CAR therapy ... -
CRISPR Cancer Therapy 2026: 32 Clinical Trials Underway, Gene-Edited T-Cells Face Efficacy and Off-Target Challenges
Hirschfeld Oncology USA Overview As of 2026, 32 clinical trials are investigating CRISPR-edited immunotherapies for cancer, predominantly focusing on ex vivo gene-edited immune cells. While these therapies generally demonstrate favorable... -
BioInformant Analyzes the Rise of Exosome Therapeutics in 2026: Potential as a Novel Modality Leveraging Intercellular Communication for New Treatments
BioInformant (Blog) USA Overview BioInformant's blog analyzes the growing role of exosome therapeutics in 2026, highlighting these extracellular vesicles as an emerging treatment modality. Exosomes, lipid bilayer vesicles 30-150 nanomete... -
AGC Biologics: Job Posting Reveals Broad Biomanufacturing Scope, Spanning Proteins to Gene Therapies
Myworkdayjobs.com USA Overview A recent student assistant job posting from AGC Biologics has inadvertently showcased the company's remarkably extensive Contract Development and Manufacturing Organization (CDMO) capabilities. The company ... -
AGC Biologics Commits Half of New Yokohama Biomanufacturing Plant to Major Long-Term Deal
Megaproject Japan Overview AGC Biologics has secured a significant multi-million dollar, long-term commercial manufacturing contract with an undisclosed pharmaceutical firm for its new Yokohama facility, set to open in 2027. This landmar... -
Drexel Symposium Highlights Injectable Self-Healing Hydrogels for Therapeutic Treg Induction and Strategies to Mitigate LNP-Induced Inflammation
Drexel University USA Overview A symposium at Drexel University showcased the development of injectable self-healing granular hydrogels optimized for inducing therapeutic regulatory T cells (Tregs), with modified B7x demonstrating dose-d... -
Lipid Nanoparticles (LNP) Overcome Nucleic Acid Respiratory and Gastrointestinal Mucosal Delivery Barriers, Opening New Avenues for Disease Treatment
MDPI Switzerland Overview Lipid nanoparticles (LNPs) are playing a crucial role in significantly enhancing the effectiveness of nucleic acid delivery to respiratory and gastrointestinal mucosa. LNPs have emerged as an effective strategy ... -
Lipid Nanoparticles (LNP) Establish Success in COVID-19 Vaccines as Cutting-Edge Technology Essential for mRNA, siRNA Delivery
Inside Therapeutics International Overview Lipid nanoparticles (LNPs) are a cutting-edge nano-drug delivery system designed to protect and efficiently deliver nucleic acids, particularly mRNA and siRNA, to target cells. Through the succe...
